Commercial

Woundcare: Intercytex plans to appoint appropriate healthcare sales partners for distribution of tissue repair products ICX-PRO and ICX-SKN to primary and secondary care markets. 

An agreement has been signed with Baxter Healthcare to secure Intercytex' supply of Tisseel®, a key raw ingredient in the production of ICX-PRO and ICX-SKN in which a fixed price and a period of exclusivity in the use of Tisseel® with allogeneic fibroblasts has been agreed.

Aesthetic Medicine: Intercytex is planning to set up its own specialist sales force to sell aesthetic medicine products in the UK and certain other countries in Europe.  For the US market the company plans to appoint suitable distribution partners.

Clinical Production and Commercial Manufacture: Intercytex has invested in its own GMP production facility in which all products needed for clinical trials are manufactured. Situated in Manchester, this capability has enabled Intercytex to scale-out its production processes alongside the clinical development programmes. An MHRA Manufacturing Licence was granted in May 2004. The Company intends to manufacture all products for Europe and the US at its own custom-built facilities. In October 2006, Intercytex was awarded a grant from the DTI to develop a robotic system with The Automation Partnership for use in later stage clinical trials and the commercial scale production of dermal papilla (DP) cells as part of the ICX-TRC procedure.